Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis
- 4 March 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (7) , 1470-1484
Abstract
Rheumatoid arthritis is one of the commonest autoimmune diseases affecting 0.8% of the population. Over the last decade the treatment of this chronic disease has been revolutionized by the use of monoclonal antibodies and fusion proteins, targeting molecules like tumour necrosis factor alpha. Nevertheless, approximately one‐third of subjects fail to respond to these therapies and therefore significant unmet medical need remains. Following a decade of use, clinical, government and regulatory agency expectations have changed for new antibodies therapies entering this highly competitive area. In this review, we discuss the current advances being made in antibody engineering and how they are being considered and used in the development of the next generation of antibodies to meet future expectations of healthcare providers, physicians and patients. Moreover, we discuss how pattern recognition receptors may provide new antibody tractable targets that may break the cycle of autoimmunity in rheumatoid arthritis.Keywords
This publication has 126 references indexed in Scilit:
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Toll-like Receptor 2 Signaling in CD4+ T Lymphocytes Promotes T Helper 17 Responses and Regulates the Pathogenesis of Autoimmune DiseaseImmunity, 2010
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)Annals of the Rheumatic Diseases, 2010
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and CancerPharmacological Reviews, 2009
- Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first‐in‐human trials of high‐risk biologicsBritish Journal of Clinical Pharmacology, 2009
- Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritisJournal of Clinical Investigation, 2008
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986